Alexander N. Shoushtari, discusses the rationale for the phase 3 CheckMate-067 trial in advanced melanoma.
Alexander N. Shoushtari, MD
Advertisement
Articles by Alexander N. Shoushtari, MD
Alexander N. Shoushtari, MD, discusses the design of the phase 3 CheckMate-067 trial in advanced melanoma.
Alexander N. Shoushtari, MD, discusses the role of nivolumab and ipilimumab in mucosal melanoma.
Alexander N. Shoushtari, MD, discusses the significance of the findings from the first-in-human trial evaluating tebentafusp, a TCR–CD3 bispecific, in patients with advanced melanoma.
Advertisement
Latest Updated Articles
Dr. Shoushtari on the Data from the First-in-Human Trial for Tebentafusp in Advanced MelanomaPublished: November 22nd 2019 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Daratumumab and Hyaluronidase Plus VRd for Newly Diagnosed Multiple Myeloma
2
NP-G1-044 Receives FDA Orphan Drug Designation for Pancreatic Cancer
3
PD-L1 Expression Is More Predictive of Response to Pembrolizumab on Metastatic Sites in High-Grade Serous Ovarian Cancer
4
Meta-Analysis Characterizes Nivolumab/Ipilimumab Hyperprogression in Renal Medullary Carcinoma
5